1 NAD+ IV Therapy delivers NAD+ directly into the bloodstream, bypassing digestion and providing immediate bioavailability
4 GLP-1 Theories on Regeneration and Proliferation The exact mechanism of GLP-1 binding to GLP-1 receptor coupled with beta cell release of insulin is unknown
Weight loss accelerates, often to 2 to 3 pounds per week during the initial weeks at each new dose
OKAVA Pharmaceuticals, the San Francisco-based manufacturer of the medication, said the landmark clinical study of the "first-in-class" device could have "profound" implications for diabetes, kidney disease, healthy aging and longevity in pets
SURMOUNT-1: Tirzepatide for Obesity The SURMOUNT-1 trial (NEJM, 2022) studied tirzepatide weight loss in 2,539 adults with obesity (without diabetes) over 72 weeks: STEP 1: Semaglutide for Obesity The STEP 1 trial (NEJM, 2021) studied semaglutide 2.4mg in 1,961 adults with obesity (without diabetes) over 68 weeks: Cross-Trial Summary Comparing across trials (with the caveat that indirect comparison has limitations): tirzepatide 15mg produced about 6 percentage points more weight loss than semaglutide 2.4mg over similar timeframes
Autophagy and mitochondrial biogenesis impairment contribute to age-dependent liver injury in experimental sepsis: dysregulation of AMP-activated protein kinase pathway